about
Statin use in giant cell arteritis: a retrospective study.A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.Large-vessel giant cell arteritis: a cohort study.Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up StudyBiologics in vasculitides: Where do we stand, where do we go from now?Biotherapies in large vessel vasculitis.Imaging of vasculitis: State of the art.Recent advances in the diagnosis and treatment of polymyalgia rheumatica.No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis.Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.Visual loss and other cranial ischaemic complications in giant cell arteritis.Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis.Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study.Incidence, Prevalence, and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy During a 26-Year Period.Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease.Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they?Increased expression of interleukin-22 in patients with giant cell arteritis.Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature.Unmet Needs in the Pathogenesis and Treatment of Vasculitides.Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature: reply.Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study.Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica.Large vessel dilatation in giant cell arteritis: a different subset of disease?MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis.Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet DiseaseCardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell ArteritisSmall-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritisComparison between colour duplex sonography findings and different histological patterns of temporal arteryMycophenolate mofetil in primary central nervous system vasculitisIs colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized studyTocilizumab for the treatment of giant cell arteritisSurvival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based studyThe therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritisEfficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control StudyRituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literatureThoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural MesotheliomaAortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CTAortic dilatation in a patient with Takayasu arteritis treated with tocilizumab
P50
Q33576127-D054637F-0ADC-4D83-88F3-C0DF9DBF39ACQ35266391-9AD1400E-B4CC-466A-BC98-D020ED168C2BQ35588160-B7164A70-6B3E-4663-8AA4-992AE3C5FB3CQ36993376-8E1CCF1F-1956-40C1-8B60-519636769B2DQ38507760-A06A2BE1-D0A8-4CA6-AAA9-CD372F808DC0Q38588942-5FB4D0BC-D32E-4253-9E80-16AB01B5245CQ38785564-1F5B5089-186E-4B85-9435-435A08137E53Q38808560-67FB7445-F4D4-4CA7-8CFB-6CF5A55AB41FQ38920083-14D3B28E-B2A5-4806-AE72-2B3E0F6B88FEQ39100312-95AE10E6-7E82-44E1-893F-0332898831AFQ39416333-C9181BAB-DC6D-47D3-AAA7-2B679FC523F8Q39892620-B0F99BBE-8916-4EC6-B912-5F45DE688544Q40491046-B33460FD-E9F7-4534-982E-ACA58E45AA79Q40740882-7B07211A-497D-426D-9619-A9B240E1E5B7Q41449043-2414A750-CFC1-49C8-9065-2D9EAE77E951Q46312581-0E52D13E-3D99-4859-9808-D55308C5DEB6Q47715350-D9B0ED4D-1F04-4B49-9BB4-C0B1B1160C9BQ47865727-2C898DF0-3D35-4F91-81AC-7B3656E5BB28Q48592090-1A9F28C4-9784-4395-9186-E59A8B38708CQ49551862-0BA3E86F-DD7C-416E-A946-CF2165317002Q51771728-F6AD320C-89A3-4CA4-98AE-E3D7A9D1FB5FQ52626174-61E1E071-C78F-4CF8-B32D-ECD4A9EB0755Q52738866-EDA632B6-7E4D-4F8F-96A7-024655E2EC98Q53355647-59BF0F44-6729-487A-9132-65FA66CE5805Q57492024-C7A158AC-EA64-406C-A5C6-9FBFAFE8493DQ58562809-AEB5EE7D-B1F2-4BF4-8A88-67C7A9187673Q85001806-A6AF75B5-27FC-43F6-9F91-CE936F67F9C0Q85944710-C7F9389A-4D63-4293-8184-65B16ED2F55CQ86977961-D67511E5-CFEA-4D9E-AD9A-2CCB9DF8E150Q88100627-6A2BB121-155D-4DFF-88F1-D2DD44BF37BDQ88420189-5EE7CD27-5DC9-445E-8B26-AC16DB5DC5E4Q90280968-E5C61EB4-7933-4A0A-B82A-081A929E9B7EQ91027289-C74EEBB9-1D62-4803-B3CC-A047B7447E62Q91062193-ABB08467-782C-49E5-B4C0-353FFD70636DQ91456167-FD4E1434-B6AD-41F6-B1C4-0B8FA7290011Q92806961-5824E398-27CF-4187-B0B8-7A9083BB1029Q93050833-5A00E415-CE3D-42BD-BC7D-A3BC75048960Q93137161-83FE6312-5890-416C-AF2A-F04C71FD63F8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesco Muratore
@ast
Francesco Muratore
@en
Francesco Muratore
@es
Francesco Muratore
@nl
Francesco Muratore
@sl
type
label
Francesco Muratore
@ast
Francesco Muratore
@en
Francesco Muratore
@es
Francesco Muratore
@nl
Francesco Muratore
@sl
prefLabel
Francesco Muratore
@ast
Francesco Muratore
@en
Francesco Muratore
@es
Francesco Muratore
@nl
Francesco Muratore
@sl
P106
P1153
7004922871
P21
P31
P496
0000-0003-0362-2668